In the original article [1], in Section 6.3, “Treatment groups received caspofungin 750 mg IV on day 1” should be “70 mg” instead of “750 mg”. We made a mistake in the process of writing. The corrected paragraph is as follows:
“Treatment groups received caspofungin 70 mg IV on day 1 followed by 50 mg IV daily or 200 mg of isavuconazole IV q8h on days 1–2 followed by 200 mg once daily.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Ellsworth, M.; Ostrosky-Zeichner, L. Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance. J. Fungi 2020, 6, 324. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).